Dr. Angel L. Comulada

Medicare patients and services

Medicare patients, 2024

29

Services billed

72

Patients’ average age

74

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 3 companies reported 29 payments worth $4,359 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Puerto Rico →

Industry-funded research

Named as a principal investigator on 14 industry-funded studies in 2025, from 5 companies. The companies reported $3,314,288 in research payments for these studies, mostly to the institutions running them.

• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
  Eli Lilly and Company · Active, not recruiting · NCT06292013
• A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
  Boehringer Ingelheim Pharmaceuticals, Inc.
• A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety of tirzepatide once weekly compared to placebo in adult participants with type 1 diabetes a…
  Eli Lilly and Company
• A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
  Eli Lilly and Company · Completed · NCT05872620
• Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
  Eli Lilly and Company · Active, not recruiting · NCT06260722
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
  Eli Lilly and Company · Active, not recruiting · NCT06383390
• A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a)…
  Novartis Pharmaceuticals Corporation
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
  Eli Lilly and Company · Completed · NCT04255433
• Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
  Novartis Pharmaceuticals Corporation
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
  Eli Lilly and Company · Active, not recruiting · NCT05556512

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Endocrinology & Diabetes clinicians in Bayamon

• Altagracia A. Alcantara Gonzalez, M.D.
• Anette Garces Dominguez, M.D
• Amelia C. Guzman-bicchi, M.D
• Nicole Z. Hernandez-cordero, MD
• Gabriel Irizarry Villafane, M.D.
• Hiram Maldonado Rivera, M.D.
• Yanira I. Marrero Mcfaline, MD
• Jorge R. Martinez, MD